Seroprevalence of antibody against poliovirus in inner-city preschool children: Implications for vaccination policy in the United States

JAMA

Volumn 275, Issue 21, 1996, Pages 1639-1645

  Chen, Robert T ^a   Hausinger, Sheryl ^c   Dajani, Adnan S ^d   Hanfling, Marcus ^c   Baughman, Andrew L ^a   Pallansch, Mark A ^b   Patriarca, Peter A ^a,e  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; CHILD; DISEASE PREDISPOSITION; HUMAN; IMMUNITY; INFANT; NORMAL HUMAN; POLIOMYELITIS; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; UNITED STATES; VACCINATION;

EID: 0029948751     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.21.1639     Document Type: Article

References (52)

1. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the Unites States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992; 14:568-579.
2. Centers for Disease Control and Prevention. Certification of poliomyelitis eradication - the Americas, 1994. MMWR Morb Mortal Wkly Rep. 1994; 43:720-722.
3. National Immunization Program. Biologies Surveillance Summary. Atlanta, Ga: CDC Information System; 1994.
4. Wright PF, Kim-Farley RJ, de Quadros CA, et al. Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med. 1991; 325:1774-1779.
5. Ogra PL. Mucosal immune response to poliovirus vaccines in childhood. Rev Infect Dis. 1984; 6(suppl):S361-S368.
6. Centers for Disease Control and Prevention. Progress toward global poliomyelitis eradication, 1985-1994. MMWA Morb Mortal Wkly Rep. 1995; 44:273-281.
7. Nightingale EO. Recommendations for a national policy on poliomyelitis vaccination. N Engl J Med. 1977;297:249-253.
8. Institute of Medicine. An Evaluation of Poliomyelitis Vaccine Policy Options. Washington, DC: National Academy of Sciences; 1988. Publication IOM 88-04.
9. National Vaccine Advisory Committee. The measles epidemic: the problems, barriers, recommendations. JAMA. 1991;266:1547-1552.
10. Zell ER, Dietz V, Stevenson J, Cochi S, Bruce RH. Low vaccination levels of US preschool and school-age children: retrospective assessments of vaccination coverage, 1991-1992. JAMA. 1994;271: 833-839.
11. US Bureau of the Census. County and City Data Book: 1994. Washington, DC: US Bureau of the Census; 1994.
12. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and The Gambia. J Infest Dis. 1995;171:1097-1106.
13. Finney DJ. Statistical Methods in Biological Assays. 2nd ed. New York, NY: Hafner Publishing; 1964:524-530.
14. Hardegree MC, Barile MF, Pittman M, Maloney CJ, Schofield F, Maclennaea R. Immunization against neonatal tetanus in New Guinea, IV: comparison of tetanus antitoxin titres obtained by hemagglutination and toxin neutralization in mice. Bull World Health Organ. 1970;43:461-468.
15. Sprent P. Applied Nonparametric Statistical Methods. 2nd ed. London, England: Chapman & Hall; 1993:28-37, 141-143.
16. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons Inc; 1981.
17. Francis TM. Evaluation of the 1954 Field Trial of Poliomyelitis Vaccine: Final Report. Ann Arbor: University of Michigan; 1957.
18. Patriarca PA, Laender F, Palmeira G, et al. Randomised trial of alternative formulations of oral poliovaccine in Brazil. Lancet. 1988;1:429-433.
19. Deming MS, Jaiteh KO, Otten MW, et al. Epidemic poliomyelitis in a well-vaccinated population. The Gambia, 1986, II: the clinical efficacy of trivalent oral polio vaccine. Am J Epidemiol. 1992;135: 393-408.
20. Sutter RW, Patriarca PA, Brogan S, et al. Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. Lancet. 1991;338:715-720.
21. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13:926-939.
22. Centers for Disease Control and Prevention. Isolation of wild poliovirus type 3 among members of a religious community objecting to vaccination - Alberta, Canada, 1993. MMWR Morb Mortal Wkly Rep. 1993;42:337-339.
23. Hovi T, Cantell K, Huovilainen A, et al. Outbreak of paralytic poliomyelitis in Finland. Lancet. 1986;1:1427-1432.
24. Fox JP, LeBlanc DR, Gelfand HM, Clemmer DJ, Potash L. Spread of a vaccine strain of poliovirus in southern Louisiana communities, In: Second International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau; 1960:144-160. Special publication 50.
25. Paul JR. The spread of attenuated polioviruses among household contacts. In: Fifth International Poliomyelitis Conference. Philadelphia, Pa: JB Lippincott Co; 1960:359-367.
26. Benyesh-Melnick M, Melnick JL, Rawls WE. Studies of the immunogenicity, communicability and genetic stability of oral polio vaccine administered during winter. Am J Epidemiol. 1976;86;112-136.
27. Gard S, Bottiger M, Lagercrantz R. Vaccination with attenuated poliovirus type 1, the CHAT strains of the natural spread within families of living vaccine strains of poliovirus. In: First International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau; 1959:350-354. Special publication 44.
28. Gelfand HM, Potash L, LeBlanc DR, Fox JP. Revised preliminary report on the Louisiana observations of the natural spread within families of living vaccine strains of poliovirus. In: First International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau; 1959:203-217. Special publication 44.
29. Horstmann DM, Niederman JC, Paul JR. Attenuated type 1 poliovirus vaccine: its capacity to infect and to spread from vaccinees within an institutional setting. JAMA. 1959;170:1-8.
30. Kimball AC, Barr RN, Bauer H, Kleinman H, Johnson EA, Cooney M. Minnesota studies with oral poliomyelitis vaccine: community spread of orally administered attenuated poliovirus vaccine strains. In: Second International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau; 1960:161-173. Special publication 50.
31. Sabin AB, Michaels EH, Spigland I, et al. Community-wide use of oral poliovirus vaccine. Am J Dis Child. 1961;101:546-567.
32. Sutter RW, Patriarca PA. Inactivated and live, attenuated poliovirus vaccines: mucosal immunity. In: Kurstak E, ed. Measles and Poliomyelitis. Vienna, Austria: Springer-Verlag; 1993:279-294.
33. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier R. Mucosal immunity induced by enhanced potency IPV and OPV. J Infect Dis. 1991;163:1-6.
34. Sutter RW, Patriarca PA, Suleiman AJM, et al. Paralytic poliomyelitis in Oman: association between regional differences in attack rate and variations in antibody responses to oral poliovirus vaccine. Int J Epidemiol. 1993;22:936-944.
35. Moriniere BJ, van Loon FPL, Rhodes PH, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet. 1993; 341:1545-1550.
36. McBean AM, Thoms ML, Albrecht P, et al. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol. 1988;128:15-28.
37. Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis. 1990;162:1291-1297.
38. Cohen-Abbo A, Culley BS, Reed GW, et al. Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Pediatr Infect Dis J. 1995;14:100-106.
39. Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA. Serum neutralizing antibody response to three experimental sequential IPV-OPV immunization schedules. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La, October 20, 1993.
40. Centers for Disease Control and Prevention. Reported vaccine-preventable diseases - United States, 1993, and the Childhood Immunization Initiative. MMWR Morb Mortal Wkly Rep. 1994;43:720-722.
41. Shalala DE. Giving pediatric immunizations the priority they deserve. JAMA. 1993;269:1844-1845.
42. Hinman AR. What will it take to fully protect all American children with vaccines? an update. Am J Dis Child. 1993;147:536-537.
43. Centers for Disease Control and Prevention. State and national vaccination coverage levels among children aged 19-35 months - United States, April-December 1994. MMWR Morb Mortal Wkly Rep. 1995;44:613-623.
44. Koprowski H, Plotkin SA, Pagano J, et al. Behavior of attenuated strain of poliomyelitis in relation to age, familial spread, and duration of immunity. In: First International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau; 1960:159-171. Special publication 44.
45. Kucharska Z, Sramova H, Zdrazilek J. Excretion of attenuated poliovirus in children vaccinated with live oral poliovirus vaccine. J Hyg Epidemiol Microbiol Immunol. 1982;1:74-82.
46. Bottiger M. Long-term immunity following vaccination with killed poliovirus vaccine in Sweden, a country with no circulating poliovirus. Rev Infect Dis. 1984;6(suppl):S548-S551.
47. Oostvogel PM, van Wijngaarden JK, van der Avoort HGAM, et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93. Lancet. 1994;344:665-670.
48. Hinman AR, Koplan JP, Orenstein WA, Brink EW, Nkowane BM. Live or inactivated poliomyelitis vaccine: an analysis of benefits and risks. Am J Public Health. 1988;78:291-295.
49. Howe CJ, Johnston RB, eds. Options for Poliomyelitis Vaccination: Summary of a Workshop. Washington, DC: Institute of Medicine Vaccine Safety Forum; 1995.
50. Marwick C. ACIP delays changing polio vaccine advice. JAMA. 1995;274-203.
51. Peter G, Halsey NA. Poliomyelitis immunization - consideration of change in the current AAP recommendation. Am Acad Pediatr News. 1995;11:13.
52. Plotkin SA. Inactivated polio vaccine for the United States: a missed vaccination opportunity. Pediatr Infect Dis J. 1995;14:835-839.